- Vistagen Therapeutics Inc VTGN completed an interim analysis of PALISADE-2, its second Phase 3 trial assessing drug candidate PH94B as an acute treatment of anxiety in adults with Social Anxiety Disorder.
- The analysis concluded that PALISADE-2 should continue as planned.
- Related: VistaGen Says Data From Late-Stage Anxiety Study 'Not Consistent' With Prior Positive Phase 2 Study.
- Independent biostatisticians reviewed unblinded data from the 140 subjects who completed PALISADE-2 before the Company paused enrollment in the study in July 2022, following the announcement of topline results from its first Phase 3 trial, PALISADE-1.
- The independent biostatisticians recommended that Vistagen continue PALISADE-2 as planned to the full enrollment of 208 subjects without adjusting the study size.
- Vistagen expects topline results from PALISADE-2 in the first half of 2023.
- Price Action: VTGN shares are up 21.8% at $0.20 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in